Ovid Therapeutics (OVID) Stock Statistics & Valuation Metrics

Ovid Therapeutics has a market cap or net worth of $43.98M. The enterprise value is $19.46M.

Ovid Therapeutics has 71,109,510 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ovid Therapeutics’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -74.58%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Ovid Therapeutics had revenue of 566.00K and earned -26.43M in profits. Earnings per share was -0.37.

In the last 12 months, operating cash flow was -49.55M and capital expenditures -52.00K, giving a free cash flow of -49.58M billion.

Ovid Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Ovid Therapeutics upcoming earnings date is Aug 18, 2025, TBA (Confirmed).

Ovid Therapeutics as a current ratio of 5.32, with Debt / Equity ratio of 24.34%

In the past 12 months, Ovid Therapeutics has paid 0.00 in taxes.

Ovid Therapeutics EV to EBITDA ratio is -0.89, with an EV/FCF ratio of -0.98.

Ovid Therapeutics has $43.00M in cash and marketable securities with $14.43M in debt, giving a net cash position of -$28.57M billion.

Gross margin is 72.99%, with operating margin of -10933.75%, and net profit margin of -4670.14%.

The average price target for Ovid Therapeutics is $2.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy